Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapirolizumab Pegol in Moderate to Severe SLE
NCT04294667Phase 3Completed
- Sponsor
- UCB
- Start
- Aug 2020
- Primary completion
- May 2024
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 25
01
Overview
A Phase 3 trial of dapirolizumab pegol in systemic lupus erythematosus (SLE), sponsored by UCB. Started Aug 2020; status: completed.
02
Drugs
dapirolizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04294667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04294667.